Related Experiment Video
Updated: Jul 9, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency
Manfredi Rizzo1, Roman Trepp, Kaspar Berneis
1Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy.
Objective:
Several studies have suggested that lipoproteins generated during the post-prandial phase are highly atherogenic, with modifications in low-density lipoproteins (LDL) size and density. In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD).
Design:
We studied in 12 hypopituitary patients with GHD and 10 healthy control subjects matched for gender, age and body mass index (BMI) post-prandial variations after a standardized meal consisting of 35% fat, 45% carbohydrate and 20% of protein (Clinutren Mix, Nestlé) and containing calories corresponding to 1/3 of estimated basal metabolic rate. Blood samples were collected at baseline and after 2 and 4h to measure plasma lipids and LDL size and subclasses by nondenaturing polyacrylamide gradient gel electrophoresis.
Results:
At baseline patients had similar plasma lipids than controls, with the exception of higher triglycerides (1.2+/-0.8 vs. 0.7+/-0.4mmol/L, p=.0024). Baseline LDL size was similar between the two groups and LDL subclass analysis revealed a small increase in LDL-IIIA (p=.0046). During post-prandial phase no significant differences were found in LDL size and subclasses in patients vs. controls with the sole exception of increased levels of LDL-IVB after 2h (p=.0295) and LDL-IIIB after 4h (p=.0478).
Conclusions:
It is, therefore, unlikely that a post-prandial variation in levels of small, dense LDL may significantly contribute to the atherogenic potential in hypopituitary patients with GHD.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Cellular Adaptation II: Hypertrophy
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Signs of Puberty
Nature and Nurture
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution